- Conditions
- Major Depression Disorder, Depression
- Interventions
- DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose
- Drug
- Lead sponsor
- Deepak C. D'Souza
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
- Interventions
- Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation, Sham transcranial magnetic stimulation
- Device
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Major Depressive Disorder
- Interventions
- Active transcutaneous vagus nerve stimulation, Sham transcutaneous vagus nerve stimulation
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 24 Years to 45 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Major Depressive Disorder
- Interventions
- SAGE-217
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 52
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 43 more
- Conditions
- Depressed Mood
- Interventions
- Not listed
- Lead sponsor
- Salma Health, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2037
- U.S. locations
- 2
- States / cities
- La Jolla, California • Laguna Hills, California
- Conditions
- Hepatic Impairment
- Interventions
- AGO178
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Major Depressive Disorder
- Interventions
- Zuranolone
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 12 Years to 17 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Flowood, Mississippi + 1 more
- Conditions
- Depressive Episodes, Bipolar I Depression
- Interventions
- SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Bryant, Arkansas • Anaheim, California + 30 more
- Conditions
- 1. Major Depressive Disorder
- Interventions
- Supplemental TMS, Standard Medication Monotherapy
- Device · Drug
- Lead sponsor
- Sheppard Pratt Health System
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Towson, Maryland
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, Brexpiprazole 1 mg, Brexpiprazole 3 mg
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- National City, California • Orlando, Florida
- Conditions
- Major Depressive Disorder
- Interventions
- Genecept Assay
- Device
- Lead sponsor
- Genomind, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Major Depressive Disorder
- Interventions
- SHX-001 Active low dose, Placebo, SHX-001 Active High dose
- Drug
- Lead sponsor
- Shenox Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
- Conditions
- Depressive Disorder, Major, Hepatitis C
- Interventions
- Cognitive behavioral treatment for depression
- Behavioral
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Depressive Disorder
- Interventions
- Saredutant succinate (SR48968C)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Interventions
- Aripiprazole + IEM (Ingestible Event Marker)
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
- Conditions
- Major Depressive Disorder
- Interventions
- vilazodone
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 38
- States / cities
- Garden Grove, California • San Diego, California • Torrance, California + 34 more
- Conditions
- Major Depressive Disorder 1
- Interventions
- Pharmacogenetic testing
- Genetic
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Major Depressive Disorder
- Interventions
- Brexpiprazole, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 70 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- Kissimmee, Florida • Miami, Florida • St Louis, Missouri + 1 more
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, Brexpiprazole, ADT
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- GeneSight Psychotropic
- Genetic
- Lead sponsor
- Assurex Health Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
- Conditions
- Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
- Conditions
- Post-traumatic Stress Disorder (PTSD)
- Interventions
- Propranolol, Prazosin
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
- Interventions
- There is no intervention in this study
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Major Depressive Disorder
- Interventions
- (2R,6R)-Hydroxynorketamine hydrochloride, Placebo
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina